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Objective: To compare the serum levels of P2-microglobulin (PZM), neopterin (NP), TNF-a and soluble receptors of 
TNF-a (sTNF-R55 and sTNF-R75) and interleukin-2 (slL-2R) in a population of intravenous drug abusers according to  
whether or not they had HIV-1 infection and to  the stage of the HIV-1 infection. 
Methods: A cross-sectional study was performed at four drug detoxification centers in Barcelona, and the HIV 
outpatient clinic at Hospital Clinic i n  Barcelona. Three cohorts of intravenous drug abusers (IVDAs)-l05 HIV-1- 
uninfected patients (cohort A), 174 with asymptomatic HIV-1 infection (cohort 6) and 39 with AIDS (cohort C)-were 
enrolled. On the first visit, the following laboratory tests were performed: hemogram and platelet count, hepatitis 
B surface antigen (HBsAg), anti-hepatitis C antibodies, BZM, NP, slL-ZR, TNF-a, and TNF receptors (sTNF-R55 and 
Results: The three cohorts were homogeneous according t o  sex, type of drug, average number of intravenous doses 
of drug in 1 day, and hepatitis B infection. Patients with AIDS were older than those of cohort A and B (p<O.OOOI). HIV- 
negative IVDAs were co-infected with hepatitis C virus less frequently than were HIV-positive IVDAs (80% versus 91%, 
p<0.03). Among HIV-I-negative IVDAs (cohort A), almost all (from 86% to  95%. depending on the marker) individual 
values were within the normal boundaries of our laboratory. With a single exception (level of sTNF-R55 in cohort 6 
compared with cohort A, p=0.15), levels of all markers were significantly higher in asymptomatic HIV-I-infected (cohort 
B) when compared with uninfected patients (cohort A), and in AIDS patients (cohort C) when compared with both cohorts 
A and 6. There was a significant positive correlation between levels of PZM and NP (r=0.56; p<O.OI), P2M and TNF 
(r=0.65, p<O.OI) and NP and TNF (r=0.76, p < O . O l ) .  There was no correlation between levels of slL-2R and levels of PZM, 
NP or TNF and its receptors. 
Conclusions: Intravenous drug abuse does not modify serum levels of P2M, NP, slL-ZR, TNF-a, and TNF receptors 
(sTNF-R55 and sTNF-R75). Levels of these markers increase significantly when an HIV-1 infection occurs and when there 
is progression to  AIDS. 
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INTRODUCTION 
Biological markers like (32-microglobulin ((32M) and 
neopterin (NP) have been useful to define the stage 
of HIV-1 infection, to predict clinical outcome (progres- 
sion to AIDS or death) and even to support therapeutic 
decisions, such as when to start antiretroviral treatment 
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and to monitor the response to this [l-71. Most of 
these studies have been performed in cohorts of male 
homosexuals [2-71 and hemo.philiacs [8]. Data among 
intravenous drug abusers (IVDAs) are scarce and 
contradictory and we stdl do not know whether intra- 
venous drug abuse by itself is able to modify the serum 
levels of some or all of the ma.rkers [9-151. 
O n  the other hand, cytokines have been implicated 
in the pathogenesis of HIV infection [16], and high 
levels of tumour necrosis factor-CX (TNF-a) and TNF 
receptors have been associated with progression of HIV 
infection [ 17,181. However, the possibility cannot be 
excluded that these increased concentrations of TNF 
could be related to secondary infections, since normal 
values of TNF have been described in asymptomatic 
HIV-infected patients [197. 
To determine the direct ef€ect of HIV infection on 
the levels of serologic markers and avoid the confound- 
ing factors (secondary infections and risk behaviors), 
three cohorts of HIV-negative IVDAs, HIV-positive 
IVDAs and IVDAs with AIDS were studied. The levels 
of NP, P2M, interleukin-2 receptor (IL-2R), TNF-a 
and TNF receptors (sTNF-REi5 and sTNF-R75) were 
measured and compared with normal values according 
to the HIV status and the stage of the HIV infection. 
PATIENTS AND METHODS 
Patients 
Between February 1986 and February 1987, 279 con- 
secutive asymptomatic outpatient IVDAs from four 
detoxification and rehabilitation programs in Barcelona 
were asked to participate in a cross-sectional evaluation 
and then in a longitudinal prospective study to assess 
the HIV infection and to monitor AIDS progression. 
This group comprised 20% of all the IVDAs who had 
started a rehabilitation program in Barcelona in this 
period. After a detoxification period, they had started 
a structured drug-free program based on psycho- 
therapy. The patients did not know their HIV status. 
Thirty-nine consecutive IvD,4s from Hospital Clinic 
i Provincial of Barcelona with AIDS were also enrolled 
in this same period. They had not suffered active 
infections within 2 months of enrollment. The diag- 
nosis of AIDS was made according to the CDC criteria 
(August 1987). Thirty-two patients had opportunistic 
infections (group IV-C2) and seven patients suffered 
from AIDS-related complex (ARC, group IV-A). 
A complete evaluation with a history of risk 
behavior, sexual activities, physical examination and 
blood samples was obtained during the first interview 
according to a predesigned protocol. Serum samples 
from AIDS patients were collected after recovery from 
the first opportunistic infection or ARC. Serum was 
frozen and stored at -30°C. Oral informed consent was 
obtained from all patients. 
We studied three cohorts of IVDAs according to 
HIV status and stage of HIV infection: cohort A, HIV- 
negative IVDAs; cohort B, asymptomatic HIV-positive 
IVDAs; and cohort C, IVDAs with AIDS. 
Laboratory tests 
The following laboratory tests were performed: hemo- 
gram and platelet count, hepatitis B surface antigen 
(HBsAg) (ELISA, Sorin), anti-hepatitis C antibodies 
(ELISA, Abott: the results confirmed with RIBA, 
Ortho), P2M (normal value: 1.1-2.8 mg/L) (RIA, 
Pharmacia), NP (normal value: < l o  nmol/L) (RIA, 
Immunotest Neopterin, Henning), serum levels of IL- 
2 R  (normal value: < 80 pmol/L) (ELISA, Immuno- 
tech), TNF-cx (normal value: < 15 pg/mL) (ELISA, 
Medgenix), and T N F  receptors (sTNF-R55 (normal 
value: < 5 ng/mL) and sTNF-R75 (c: 12.5 ng/mL)) 
(ELISA, E Hoffman-La Roche AG). HIV infection was 
determined by ELISA and confirmed by Western blot. 
Normal values were previously determined in a healthy 
population (mean k 95% CI) in our laboratory, and are 
those used in the daily routine. 
Statistical analysis 
The data were introduced into a database (dbase IV) 
and analyzed by the SPSS statistical package (SPSS 
4.0 1990). Non-parametric tests (Kruskal-Wahs test 
and U-Mann-Whitney test) were used for continuous 
variables. Categorical data were analyzed with the 
chi-square test. Pearson’s correlation coefficient was 
calculated to assess the correlation between continuous 
variables. Those variables associated with the increase 
of values of NP, P2M, IL-2R, TNF-cx and TNF 
receptors (sTNF-R55 and sTNF-R75) in the univariate 




One hundred and five out of 318 IVDAs were HIV 
negative (33%) (cohort A), 174 were HIV positive 
(55%) (cohort B) and 39 suffered from AIDS (cohort 
C). Table 1 shows the clinical characteristics of all 
the patients at baseline. Table 2 indicates the AIDS 
diagnostic criteria of IVDAs from cohort C. AU IVDAs 
from cohort B had an asymptomatic HIV infection 
and had normal physical examination, except for the 
presence of lymph node enlargement in at least two 
regions in 57% of cases (therefore they belonged to 
groups I1 or 111 from the 1987 C D C  classification 
criteria of HIV infection). The median age was 24 years 
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Table 1 Demographic characteristics of the patients included in the study 
Cohort A Cohort B Cohort C P 
Number of cases 
Sex (male/female) 
Age.' 
Hirtory of acute hepatitis 
















121/53 28/11 0.48 
11 5 (66%) 23 (64%) 0.14 
24 (16-38) 30 (23-46) 0.0001 





4.5 k 3 NA 0.22d 
Months of intravenous 
Leukocytes ( X  109/L) 8.6k2.46 7.27k 2.1 6 4.69k2.06 0.0001 
Hematocrit' 54k 4.2 54i4.38 34k6.2 0.0001 
drug abuseJ 40 (2-144) 60 (2-156) 72 (4-142) 0.00 5 
Lymphocytes ( X  10'/L)e 2.810.8 2.4i0.9 1.02io.s 0.0001 
Platelets ( X  I C)'2/L)e 250164 231 k7.5 170+ 63 0.03 
Positive HBsAg (96) 27 (27%) 30 ( 1  8%) 7 (18%) 0.18 
Positive HCV Ab (%)g 79 (80%) 152 (91%) 34 (87%) 0.02 
Cohort A, HIV-negative IVDAs; cohort B, asymptomat~c HIV-positive IVDAs; cohort C, IVDAs with AIDS. NA, not available. 
'Median (range). bP values comparing cohort A and B was 0.68. 
'Urethritis and/or syphihs. dP  value comparing cohort A and B. 
'Mean i standard deviation. ' P  value comparing cohort A and B was 0.62. 
KNot performed in seven and eight patients of cohort A and B respectively. 
Table 2 AIDS diagnostic events' in the 39 IVDAs with 
AIDS (cohort C) 
Diagnostic criteria Cases (%) 
Extrapulinonary tuberculosis 
AIDS-related complex (ARC) 
Pnerritiorystis rarinii pneumonia 













~ ~ ~~~~~~ 
ARC (group IV-A): symptomatic disease characterized by the 
presence of fevers >38.5"C lasting for more than 1 month, weight 
loss >10% body weight or >4.5 kg, diarrhea lasting for more than 
.'CDC criteria, August 1987. 
1 131011th. 
(range 26-38) in cohorts A and B and 30 years in 
cohort C (range 23-46) (p<O.OOOl).  There were 229 
male (72%) and 89 female (28%) IVDAs enrolled. 
There were no  differences in sex, history of acute 
hepatitis, sexually transmitted diseases (STD), type of 
drug, and number of intravenous doses of drug in 1 day, 
between cohorts A and B. The duration ofintravenous 
drug abuse was significantly higher in cohorts B and C 
than in cohort A (p<0.005). These differences in the 
duration of intravenous drug abuse were also observed 
between the three cohorts (pCO.02).  Cohorts B and C 
had significantly lower levels of leukocytes, lymphocytes 
and platelets, and were co-infected with hepatitis C 
virus (HCV) more frequently than were IVDAs iron1 
cohort A. There were no statistically significant 
differences in the level of co-infection with hepatitis I3 
virus (HBV). 
Serologic markers of immune activation 
Overall, there were differences between the three 
cohorts in the values of P2M and NP Table 3 shows 
the values of these serologic markers. The most striking 
difference was between cohort C (AIDS patients) and 
the other two cohorts, but the differences between 
HIV-positive (cohort B) and HIV-negative (cohort A) 
IVDAs were also significant (p<O.OOI, Mann-Whitney 
test). The median value of P2M and NP of HIV- 
negative cases (cohort A) were similar to those of the 
general population. Only 4% and 7% of HIV-negative 
IVDAs (cohort A) had increased levels of P2M and NP, 
respectively. However, these proportions were 33% and 
43%) in asymptomatic HIV-positive patients (cohort B). 
In  order to avoid the duration of intravenous drug 
abuse being a confounding factor, two sub-analyses 
were performed. First, the subgroup of asymptomatic 
HIV-positive patients (cohort B) with normal levels of 
P2M was compared with those with increased values. 
The same analysis was performed with NP. There was 
no difference in age, sex, history of acute hepatitis, type 
of drug, number of intravenous doses of drug in I day 
or duration of intravenous drug abuse (data not shown). 
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Table 3 Serum levels of serological markers of immune activation according to HIV status and stage of the HIV-1 infection 
in the three cohorts of the study 
Cohort Aa Cohort B’ Cohort c” PC 
82-Microglobulin (mg/L) 1.9f0.5 (4%) 2.5f0.6 4.8 f 2.21 0.0001 
sIG2R @rnol/L) 56425 (14%) 71 f 3 1  91 t 3 1  0.0001 
TNF-a @g/mL) 71t6.6 (8%) 9 f 9  44 t 39 0.0001 
rTNF-R55 (r!g/inL) 2.8f 1 (5%) 3.1 t0 .8  6.2f2.6 0.0001 
sTNF-R75 (ng/mL) 6.1 k2.6 (5%) 7.7f3.3 16.3 k7.2 0.0001 
0.0001 Neopterin (nmol/L) 6.8f1.7 (7%) 9.6f3.6 29.5k31.5 
Cohort A, HIV-negative IVDAs; cohort B, asymptomatic HIV-positive IVDAs; cohort C, IVDAs with AIDS. 
“Meanfstandard deviation. bPercentage above the upper limit of normal. ‘ P  comparing all the groups (Kruskal-Wallis test); 
P values of all comparisons between cohort A and B are < 0.05 with the exception of TNF-R55 (U-Mann-Whitney test). 
Second, an analysis of patients with less than 3 years of 
intravenous drug abuse was performed. The differences 
in levels of p2M and NP between HIV-negative IVDAs 
(cohort A) and HIV-positive IVDAs (cohort B) per- 
sisted. Correlations between duration of intravenous 
drug abuse and levels of serologic markers were very 
low (versus P2M, r=0.11; versus NP, r=-0.01). 
HCV-positive IVDAs had significantly higher levels 
of p2M than did HCV-negative IVDAs (p<0.03). 
Levels of NP were not different between these two 
groups. Levels of p2M and NP were not different 
between HBsAg-positive and HBsAg-negative patients. 
When the variables that showed differences in the 
levels of p2M in the univariate analysis (HCV infection 
and HIV infection) were introduced into a multivariate 
analysis, only the HJV infection remained statistically 
significant (p<0.0001). 
HIV-positive IVDAs (cohort B) with lymph 
node enlargement had statistically significantly higher 
levels of NP than patients without this abnormality 
(pC0 .02) .  The levels of R2M were not statistically 
different between HIV-positive IVDAs (cohort B) with 
and without lymph node enlargement. 
Cytokines 
Table 3 shows the differences in cytokine levels between 
the cohorts. There were also differences between all the 
cohorts in the levels of sII,-2R, TNF and TNF 
receptors, although the values in patients without AIDS 
(cohorts A and B) were similar to those of the general 
population. sIL-2R levels were increased in 30% of 
asymptomatic HIV-positive patients (cohort B) and in 
14% of HIV-negative cases (cohort A). Only 8% of 
HIV-negative (cohort A) and 13% of asymptomatic 
HIV-positive cases (cohort B) had TNF levels higher 
than normal (< 15 pg/mL), but they were never higher 
than 50 pg/mL. However, 64% of patients with AIDS 
(cohort C) had TNF levels higher than 15 pg/ iL,  and 
36% had levels higher than 50 pg/mL. Three out of 
seven cases of IVDAs with ARC (cohort C) had hgh  
levels of TNF, with similar values to those of IVDAs 
who had suffered an opportunistic infection (cohort 
C). No patient from cohort C had acute infections 
when the serum samples were collected. 
Levels of TNF and sTNF-55R were higher in 
asymptomatic HIV-positive IVDAs (cohort B) with 
lymph node enlargement than in cases without it ( p <  
0.04 for both). There were no differences in the levels 
of sIL-2R (p=0.24) or sTNF-75R ( ~ ~ 0 . 0 9 ) .  
Overall, there were no differences in the levels 
of cytokines between HCV- or HBsAg-positive and 
-negative patients. 
Correlation between different surrogate markers 
There was a strong correlation between levels of p2M 
and NP ( ~ 0 . 5 6 ;  p<O.Ol). The values of serologic 
markers were also correlated with levels of TNF and its 
receptors (P2M versus TNF, ~ 0 . 6 5 ,  p<O.O1; NP 
versus TNF r=0.76,p<0.01). There was no correlation 
between levels of sIL-2R and levels of p2M, NP or 
TNF and its receptors. 
DISCUSSION 
The roles of recent hepatitis [13] and risk behaviors 
[14,15] in the variation in serologic markers and 
cytokines are thought to be important, since these 
considerations could modify the reference values of 
progression markers and could influence the results of 
the clinical trials. The data shown in t h s  study suggest 
that HIV infection itself, and not drug abuse or 
previous hepatitis, is the cause of the increase of these 
values in IVDAs. The values of P2M, NP, sIL-2R and 
TNF of HIV-negative IVDAs (cohort A) are similar in 
this study to those of the general population, and the 
proportion ofpatients with abnormal values is very low 
(around 10%). However, over 30% of asymptomatic 
HIV-positive IVDAs (cohort B) have values higher than 
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normal. There were no differences in risk behaviors or 
in clinical characteristics between these subgroups of 
patients and the HIV-positive cases with normal values, 
so the HIV infection itself is probably the cause of these 
changes. 
The differences in serologic markers and cytokines 
between HIV-negative (cohort A) and asymptomatic 
HIV-positive patients (cohort B) of this study could be 
attributed to the different duration of intravenous drug 
abuse. However, the duration of intravenous drug abuse 
was not statistically different between HIV-positive 
patients with normal values of P2M and those with 
high levels, and the differences persisted if the analysis 
was performed only in patients with less than 3 years 
of intravenous drug abuse. These results suggest that 
duration of intravenous drug abuse itself does not 
influence the levels of P2M, NP and cytokines in these 
patients. 
The influence of co-infection with other viruses 
on the level of surrogate markers could be important, 
due to the frequency of this co-infection in HIV- 
positive IVDAs. Our  cohorts showed rates of co- 
infection with HBV and HCV of 20% and 83%>, 
respectively These figures were similar to those mea- 
sured in IVDAs in other studies [20-241, although the 
HBV ratio was higher than expected. The prevalence 
of HBsAg in IVDAs ranged between 5% and 15% 
[20,21]. Infections with other viruses such as HTLV-I, 
HTLV-I1 and HIV-2 are currently very unusual in 
Spain and were not studied [25-271. The differences 
in the levels of P2M between HCV-positive and 
-negative patients could be attributed to the co- 
infection with HIV, because HCV infection was more 
frequently observed in HIV-positive patients. When 
the multivariate analysis was performed, only HIV 
infection remained statistically significant. 
P2M is the light chain of the major histocompati- 
bility complex class I molecule, and in part originates 
in the turnover of the lymphocytes [28]. Flegg et a1 
[ t4]  suggest that changer in P2M levels may reflect 
differences in drug-injecting behavior and are not 
influenced solely by HIV status or progression. The 
data from the present study show that the duration of 
intravenous drug abuse, type of drug and nuniber of 
doses do not influence the level of P2M. Moreover, 
only 4% of HIV-negative IVDAs (cohort A) versus 33% 
of asymptomatic HIV-positive IVDAS (cohort B) had 
high levels of P2M. These results are similar to those 
reported in other studies [13,15]. The differences in the 
predictive power of P2M in IVDAs and homosexual 
HIV-positive [lo-121 patients cannot be attributed to 
intravenous drug abuse. 
Other authors report that frequent intravenous 
drug use may be independently associated with a small 
elevation of serum NP levels [l5]. NP  is a product of 
GTP catabolism that is derived from macrophages and 
B-cells stimulated with interferon-y [29] and has been 
found to be of prognostic value in progression to AIDS 
[11,12]. Asymptomatic HIV-positive IVDAs (cohort B) 
had significantly higher levels than HIV-negative cases 
(cohort A), and 43% of the former had increased levels 
of NP. This supports the evidence on the important 
role of macrophages in the pathogenesis of AIDS. 
Studies of CD4+ cell subsets suggest that during 
the early stages of HIV-1 infection the T h l  subsets 
predominate, with production of IL-2 and inter- 
feron-y, but with the progression of the disease these 
are replaced by IL-4 and IL-10 (type 2 cytokine). 
This could lead to a reduction in the cell-mediated 
immunity needed for continued suppression of HIV 
replication [30-331. IL-2 is a cytokine secreted by 
activated T h l  cells that interacts with specific high- 
affinity sIL-2R on the surface of other activated T-cells 
[1,34]. The studies of viral dynamics of HIV infection 
show that there is a continuous and rapid turnover of 
virus and CD4 lymphocytes in HIV infection [35-371, 
and serum increases and lymphoid cell surface losses 
of sIL-2R have been reported in HIV-infected cases. 
These immunologic changes explain the value of 
sIL-2R as prognostic marker of AIDS progression [6]. 
Our study shows that less than 15% of HIV-negative 
IVDAs (cohort A) had high levels of s I L - ~ R ,  while 
there are increased levels of sIL-2R in 30% of asymp- 
tomatic HIV-positive patients (cohort B) and 50% of 
IVDAs with AIDS (cohort C). These differences are 
statistically significant. Riinaniol et a1 [38] also found 
an increase of sIL-2R serum levels with HIV disease 
progression. However, in this study only 8% of patients 
were IVDAs. These data suggest that serum levels of 
sIL-2R probably increase with the progression of the 
HIV disease. 
TNF-cx has been implicated in the pathogenesis of 
HIV infection [7]. Thea et a1 [39] found higher levels 
o fTNF and its receptors in asymptomatic HIV patients 
than in AIDS patients or controls. However, this study 
was done in a cohort of African women, who are more 
likely to manifest higher levels of immune activation 
due to parasitic and other co-infections. Other studies 
have found higher levels of TNF in AIDS patients and 
suggest that the increase in the level of T N F  in AIDS 
cases could be attributed to secondary infection [19]. 
Zangerle et a1 report increased serum concentrations of 
sTNF-55R and sTNF-75R [18], and suggest that these 
elevated serum levels are linked to immune activation, 
in which synergistic actions of interferon-y and the 
T N F  system are likely to play an iniportant role. 
Kimaniol et al [38] also found that the sTNF-55R and 
the sTNF-75R serum levels increased with HIV disease 
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progression. The present study shows that the differ- 
ence between HIV-negative (cohort A) and positive 
(cohort B) patients is small (and in the case of 
sTNF-55R, does not exist). However, AIDS patients 
(cohort C), including A R C  patients, show high levels 
of TNF and sTNF receptors. This suggests that the 
increase of HIV replication itself and the immune 
activation in advanced disease can produce high 
levels of TNF. In this study the patients did not have 
acute infection when the serum was collected. These 
differences between our results concerning the levels 
of TNF and its receptors and those of Thea et a1 [39] 
could be clarified in future longitudinal studies in order 
to explain the relevance of TNF in the different stages 
of the disease. 
The results of this study demonstrate a strong 
correlation between the serologic markers and T N F  
and sTNF receptors, and it IS likely that these cor- 
relations reflect a common pathway of the continuous 
immune activation of HIV infection [I 81. 
According to the data &om this study, risk behaviors 
such as use of drugs, duration of intravenous drug 
abuse, and type of drugs, and HBV/HCV chronic 
infections, do not produce a significant change in the 
levels of serologic markers. The immune activation of 
HIV-1 infection may explain by itself the increase in 
these values in IVDAs. These surrogate markers could 
be used as markers of immune activation in HIV-I- 
infected IVDAs. Their role as progression markers and 
their use as a tool to monitor therapeutic decisions 
should be determined in longitudinal studies. 
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